Evaluation of microRNA-146a expression in acute lymphoblastic leukemia

Abstract

MicroRNAs (miRNAs) play an essential role in the development and progression of acute lymphoblastic leukemia (ALL), and could serve as disease biomarkers and therapeutic targets. The function of miR-146a in lymphoid differentiation has been here with discussed. However, the role of this miRNA in the outcome of ALL is not well understood. Peripheral blood of 48 patients with ALL and 20 age- and sex-matched healthy control subjects was used to accurately evaluate the expression of miR-146a by stem-loop Real time PCR. No statistically significant difference was found between patients and controls in total miR-146a expression. The expression of miR-146a was high (18.75%), low (27.08%) and not different (54.17%) in ALL patients. Our analysis indicated no association between the expression of miR-146a and any prognostic factors such as WBC/PLT counts, Hb, fusion genes (P190 and some translocations) with ALL type. This study revealed that miR-146a cannot be an independent factor for predicting the outcome of ALL patients. We suggest a multi-parameter analysis including miRNAs, transcription factors and critical genes to achieve a precise clinical panel for prognostic values.

Keywords

miR-146a / acute lymphoblastic leukemia / prognostic marker

References

[1] Béres N J, Szabű D, Kocsis D, Szűcs D, Kiss Z, Müller K E, Lendvai G, Kiss A, Arató A, Sziksz E, Vannay Á, Szabó A J, Veres G (2016). Role of Altered Expression of miR-146a, miR-155, and miR-122 in Pediatric Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis, 22(2): 327–335

[2] Bottoni A, Calin G (2013). A Calin G. MicroRNAs as main players in the pathogenesis of chronic lymphocytic leukemia. MicroRNA, 2(3): 158–164

[3] Contreras J, Palanichamy J, Tran T, Fernando T, Rodriguez-Malave N, Goswami N, Arboleda V A, Casero D, Rao D S (2015). MicroRNA-146a modulates B-cell oncogenesis by regulating Egr1. Oncotarget, 6(13): 11023–11037

[4] Daschkey S, Röttgers S, Giri A,Bradtke J , Teigler-Schlegel A, Meister G, Borkhardt A, Landgraf P (2013). MicroRNAs distinguish cytogenetic subgroups in pediatric AML and contribute to complex regulatory networks in AML-relevant pathways. Plos One, 8(2): 276–276

[5] de Oliveira J C, Scrideli C A, Brassesco M S, Morales A G, Pezuk J A, de Paula Queiroz R, Yunes J A, Brandalise S R, Tone L G(2012). Differential miRNA expression in childhood acute lymphoblastic leukemia and association with clinical and biological features. Leuk Res, 36(3): 293–298

[6] Du J, Lu C, Cui G, Chen Y, He J (2013). DNA repair gene XRCC1 polymorphisms and susceptibility to childhood acute lymphoblastic leukemia: a meta-analysis. Chin J Cancer Res, 25(4): 405–415

[7] Duyu M, Durmaz B, Gunduz C, Vergin C,Yilmaz Karapinar D , Aksoylar S, Kavakli K, Cetingul N, Irken G, Yaman Y, Ozkinay F, Cogulu O(2014). Prospective evaluation of whole genome microRNA expression profiling in childhood acute lymphoblastic leukemia. BioMed Research International, 2014(1):967585–967585

[8] Ebert B L (2010). Genetic deletions in AML and MDS. Best Pract Res Clin Haematol, 23(4): 457–461

[9] Fallah P, Arefian E, Naderi M, Aghaee-Bakhtiari S H, Atashi A, Ahmadi K, Shafiee A, Soleimani M (2013). miR-146a and miR-150 promote the differentiation of CD133+ cells into T-lymphoid lineage. Mol Biol Rep, 40(8): 4713–4719

[10] Faraoni I, Antonetti F R, Cardone J, Bonmassar E (2009). miR-155 gene: a typical multifunctional microRNA. Biochimica et Biophysica Acta (BBA)-. Molecular Basis of Disease., 1792(6): 497–505

[11] Ferreira A, Moura L, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin G A, Ivan C, Covas D T, Kashima S, Castro F A (2014). ApoptomiRs expression modulated by BCR–ABL is linked to CML progression and imatinib resistance. Blood Cells Mol Dis, 53(1): 47–55

[12] Friedmann A M, Weinstein H J (2000). The role of prognostic features in the treatment of childhood acute lymphoblastic leukemia. Oncologist, 5(4): 321–328

[13] Gaballa M R, Besa E C (2014). Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide. Ann Hematol, 93(5): 723–733

[14] Ghose J, Bhattacharyya N P (2015). Transcriptional regulation of microRNA-100, -146a, and -150 genes by p53 and NFkB p65/RelA in mouse striatal STHdh(Q7)/ Hdh(Q7) cells and human cervical carcinoma HeLa cells. RNA Biol, 12(4): 457–477

[15] Hagag A A, Nosair N A, Ghaith F M, Elshenawy E H (2014). Prognostic value of protease activated receptor-1 in children with acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis, 6(1): e2014029

[16] Han B W, Feng D D, Li Z G, Luo X Q, Zhang H, Li X J, Zhang X J, Zheng L L, Zeng C W, Lin K Y, Zhang P, Xu L, Chen Y Q (2011). A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum Mol Genet, 20(24): 4903–4915

[17] Hauptman N, Glavac D (2013). MicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancer. Radiol Oncol, 47(4): 311–318

[18] Jurado-Camino T, Córdoba R, Esteban-Burgos L, Hernández-Jiménez E, Toledano V, Hernandez-Rivas J A, Ruiz-Sainz E, Cobo T, Siliceo M, Perez de Diego R, Belda C, Cubillos-Zapata C, Lopez-Collazo E (2015). Chronic Lymphocytic Leukemia: A Paradigm of Innate Immune Cross-Tolerance. J Immunol, 194(2): 719–727

[19] Li P, Wang X (2013). Role of signaling pathways and miRNAs in chronic lymphocytic leukemia. Chin Med J (Engl), 126(21): 4175–4182

[20] Li X, Sanda T, Look A T, Novina C D, von Boehmer H (2011). Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. J Exp Med, 208(4): 663–675

[21] Mavrakis K J, Van Der Meulen J, Wolfe A L, Liu X, Mets E, Taghon T, Khan A A, Setty M, Rondou P, Vandenberghe P, Delabesse E, Benoit Y, Socci N B, Leslie C S, Van Vlierberghe P, Speleman F, Wendel H G (2011). A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet, 43(7): 673–678

[22] Mei Y, Gao C, Wang K, Cui L, Li W, Zhao X, Liu F, Wu M, Deng G, Ding W, Jia H, Li Z (2014). Effect of microRNA‐210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci, 105(4): 463–472

[23] Musilova K, Mraz M (2015). MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia, 29(5): 1004–1017

[24] Naderi M, Abdul T H, Soleimani M, Shabani I, Hashemi S M (2015). A Home-brew Real-time PCR Assay for Reliable Detection and Quantification of Mature miR-122. Appl Immunohistochem Mol Morphol, 23(8):60–66

[25] Portell C A, Wenzell C M, Advani A S (2013). Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol, 5: 5–11

[26] Rosato P, Anastasiadou E, Garg N, Lenze D, Boccellato F, Vincenti S, Severa M, Coccia E M, Bigi R, Cirone M, Ferretti E, Campese A F, Hummel M, Frati L, Presutti C, Faggioni A, Trivedi P (2012). Differential regulation of miR-21 and miR-146a by Epstein–Barr virus-encoded EBNA2. Leukemia, 26(11): 2343–2352

[27] Saki N, Abroun S, Soleimani M, Mortazavi Y, Kaviani S, Arefian E (2014). The roles of miR-146a in the differentiation of Jurkat T-lymphoblasts. Hematology., 19(3): 141–147

[28] Schotte D, De Menezes R X, Moqadam F A, Khankahdani L M, Lange-Turenhout E,Chen C , Pieters P, Den Boer M L(2011) MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica, 96(5):703–711

[29] Schotte D, Lange-Turenhout E A, Stumpel D J, Stam R W, Buijs-Gladdines J G, Meijerink J P, Pieters R, Den Boer M L (2010). Expression of miR-196b is not exclusively MLL-driven but especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica. 95(10):1675–1682

[30] So A Y L, Zhao J L, Baltimore D (2013). The Yin and Yang of microRNAs: leukemia and immunity. Immunol Rev, 253(1): 129–145

[31] Starczynowski D T, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells R A, Buckstein R, Lam W, Humphries R K, Karsan A (2010). Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med, 16(1): 49–58

[32] Visone R, Rassenti L Z, Veronese A, Taccioli C, Costinean S, Aguda B D, Volinia S, Ferracin M, Palatini J, Balatti V, Alder H, Negrini M, Kipps T J, Croce C M (2009). Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood, 114(18): 3872–3879

[33] Wang Y, Li Z, He C, Wang D, Yuan X, Chen J, Jin J (2010). MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis, 44(3): 191–197

[34] Xiong Q, Yang Y, Wang H, Li J, Wang S, Li Y, Yang Y, Cai K, Ruan X, Yan J, Hu S, Fang X (2014). Characterization of miRNomes in acute and chronic myeloid leukemia cell lines. Genomics Proteomics Bioinformatics, 12(2): 79–91

[35] Yan J, Jiang N, Huang G, Tay J L S, Lin B, Bi C, Koh G S, Li Z, Tan J, Chung T H, Lu Y, Ariffin H, Kham S K Y, Yeoh A E J, Chng W J (2013). Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia. Br J Haematol, 163(1): 93–103

[36] Yin J Y, Tang Q, Qian W, Qian J, Lin J, Wen X M,  Zhou J D, Zhang Y Y, Zhu X W, Deng Z Q (2014). Increased expression of miR-24 is associated with acute myeloid leukemia with t (8; 21). Int J Clin Exp Pathol, 7(11): 8032–8038

[37] Zhang H, Luo X Q, Zhang P, Huang L B, Zheng Y S, Wu J, Zhou H, Qu L H, Xu L, Chen Y Q (2009). MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS ONE, 4(11): e7826

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg